Ceremed, Inc. Traditional 510(k) - Adaptain FastWrap[™], Envelock[™]

Page 6 - 1

NOV 2 7 2012

VI - 510 (K) SUMMARY

Submitted by:

Chelsea Mitchell Ceremed, Inc.

3643 Lenawee Ave.

Los Angeles, California 90016

Tel: (310) 815-2125 Fax: (310) 815-2130

Contact Person:

Chelsea Mitchell

Date Prepared

August 20, 2012

Common/Usual Name:

Soluble Synthetic Polymer Implant Material

Proprietary Name:

Adaptain FastWrap [™], Envelock [™]

Regulation Number:

21 CFR 874.3620

Regulation Name:

Ear, nose and throat synthetic polymer

material

Regulatory Class:

II

Product Code:

KHJ

Predicate Device:

Ceremed, Inc.
Ceretene [™] Soluble Implant Material

(K120220)

Description of the device:

Adaptain FastWrap [™] is an odorless, opaque wax-like material designed to be utilized directly out of the package. It is best used immediately following removal from the package, and can be softened and increased in stickiness by warming and by additional. handling and manipulation, if so desired.

Adaptain FastWrap [™] is comprised of a sterile mixture of water-soluble alkylene oxide copolymers (AOC PolymerBlend[™]). Adaptain FastWrap [™] contains no other additives or colorants. Adaptain FastWrap [™] is formed in bars and sheets of various sizes with weights ranging from 0.5 to 5 grams each.

Adaptain FastWrap[™] is provided sterile by irradiation and must not be resterilized.

V122561 70FZ Page 6-2

Ceremed, Inc. Traditional 510(k) – Adaptain FastWrap $^{\text{TM}}$, Envelock $^{\text{TM}}$

Intended use:

Adaptain FastWrap [™] is indicated for use as a water-soluble implant material and as a water-soluble space occupying material as an adjunct during the natural healing process.

Substantial equivalence:

The non-clinical evaluations used to determine substantial equivalence included indications, intended use, design, materials, sterilization, and performance. The comparison demonstrates that the device in this submission is identical in design, materials, indications, performance and sterilization to the predicate Adaptain Soluble Implant Material (K120220).



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-002

Ceremed, Incorporated % Ms. Chelsea Mitchell Vice President, Regulatory Affairs 3643 Lenawee Avenue Los Angeles, California 90016

November 27, 2012

Re: K122561

Trade/Device Name: Adaptain FastWrap[™], Envelock[™]

Regulation Number: 21 CFR 874.3620

Regulation Name: Ear, nose, and throat synthetic polymer material

Regulatory Class: Class II

Product Code: KHJ
Dated: October 18, 2012
Received: October 19, 2012

Dear Ms. Mitchell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Peter D. Rumm -S

Mark N. Melkerson
Acting Director
Division of Surgical Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Ceremed, Inc. $Traditional\ 510(k)$ – $Adaptain\ FastWrap^{^{TM}}$, $Envelock^{^{TM}}$

<u>V. INDICATIONS FOR USE:</u>

510 (k) Number (if known): K12256	61	
<u>Device Name:</u> Adaptain FastWrap [™] , Envelock [™]		
Indications For Use: Adaptain FastWrap ™ is indicated for twater-soluble space occupying material		er-soluble implant material and as a unct during the natural healing process.
Prescription UseX (Per 21 CFR 801.109)	OR	Over-The-Counter Use(Optional Format 1-2-96)
•		
(PLEASE DO NOT WRITE BELOW IF NEEDED.)	THIS LINI	E – CONTINUE ON ANOTHER PAGE
concurrance of cdrh, office Davi		ause
(Division S	-	
Division of 510(k) Numb	· ·	
	•	Division Sign-Off
		510(k) Number